Safety evaluation of an Ayurvedic medicine, Arogyavardhini vati on brain, liver and kidney in rats

Kumar, Gajendra; Srivastava, Amita; Sharma, Surinder K.; Gupta, Yogendra Kumar

doi:10.1016/j.jep.2012.01.004

Cited by 39 publications

(40 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings of the study showed that Arogyavardhini vati in the doses equivalent to 10 times of the human dose, administered to rats for 28 days, do not have appreciable toxicological effects on brain, liver, and kidney. [9]…”

Section: Introductionmentioning

confidence: 99%

The hypolipidemic activity of Ayurvedic medicine, Arogyavardhini vati in Triton WR-1339-induced hyperlipidemic rats: A comparison with fenofibrate

Kumar¹,

Srivastava²,

Sharma³

et al. 2013

J Ayurveda Integr Med

Self Cite

View full text Add to dashboard Cite

Background:Hyperlipidemia is a major risk factor of coronary heart disease. Currently available hypolipidemic drugs have been associated with number of side effects. Arogyavardhini vati, an Ayurvedic polyherbal formulation has been used for liver disorders. Therefore, present study was designed to evaluate the effect of Arogyavardhini vati in Triton WR-1339-induced hyperlipidemia in rats.Objectives:Anti-hyperlipidemic activity evaluation of Arogyavardhini vati against Triton WR-1339-induced hyperlipidemia in rats.Materials and Methods:Overnight fasted male Wistar rats (150-200 g) were randomly divided into normal control group [4% Dimethyl Sulfoxide (DMSO), i.p.], positive control group (Triton WR-1339 in 4% DMSO, 400 mg/kg, i.p.), standard drug treated (fenofibrate 65 mg/kg, p.o. for 7 days after inducing hyperlipidemia) and Arogyavardhini vati treated (50, 100, 200 mg/kg, p.o. for 7 days after inducing hyperlipidemia). Rat doses were calculated by extrapolating the equivalent human dose (therapeutic dose, sub-maximum, and maximum dose). Serum total cholesterol, triglyceride, low-density lipoprotein (LDL), high-density lipoprotein HDL, liver malondialdehyde (MDA), and glutathione (GSH) levels were estimated at end of experiments.Results:Arogyavardhini vati significantly decreased serum cholesterol, triglyceride, LDL, and C-reactive protein (CRP) and significantly increased serum HDL in a dose-dependent manner. Decreased MDA and increased GSH levels in liver were observed at all doses of Arogyavardhini vati (50, 100, 200 mg/kg) and fenofibrate-treated groups when compared with Triton-treated group. Atherogenic Index (AI) level was significantly decreased in fenofibrate and Arogyavardhini vati (200 mg/kg) treated rats when compared with normal control.Conclusion:Arogyavardhini vati, a traditionally used Ayurvedic medicine may be a useful therapy for hypercholesterolemia through reducing oxidative stress (decreasing MDA and increasing GSH) and lipid levels.

show abstract

Section: Introductionmentioning

confidence: 99%

The hypolipidemic activity of Ayurvedic medicine, Arogyavardhini vati in Triton WR-1339-induced hyperlipidemic rats: A comparison with fenofibrate

Kumar¹,

Srivastava²,

Sharma³

et al. 2013

J Ayurveda Integr Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…It consists of Terminalia chebula (Haritaki) Terminalia bellerica (Bibitaka), Emblica oficinalis (Amalaki), Aspalitum (SilajatuSuddha), Commipora wightill (Guggulu Shuddha), Ricinus communis (Eranda), Picrorrhiza kurroa (Katuka) leaf juice of Azadiracta indica (Nimba) andmetals including Shuddha Rasa (purified mercury), Shuddha Gandhaka (purified sulphur), Laua Bhasma (irom compound in ash form), Abhraka Bhasma (mica in ash form), and Tamra Bhasma (copper compounds in ash form), Abhraka Bhasma (mica in ash form), and Tamra Bhasma (copper compounds in ash form), Abhraka Bhasma (mica in ash form), and Tamra Bhasma (copper compounds in ash form). An experimental study clearly demonstrated the protective effect of well-known Arogyavardhini vati against CCI4 induced hepatotoxicity in rats [23,24] it has proven anti-oxidant properties. It is safe in use although contains copper and mercury.…”

Section: Ayurveda Products/herbs For Hepato Billiary Disorders Arogyamentioning

confidence: 99%

Ayurvedic Intervention for Hepatobiliary Disorders: Current Scenario and Future Prospect

Panda¹,

Gc²,

Mv³

2017

J Tradi Med Clin Natur

View full text Add to dashboard Cite

Hepatobiliary diseases include a heterogeneous group of diseases of the liver and biliary system affecting more than 50% population ranging from Non-alcoholic fatty liver diseases, gall stone, hepatitis to hepato-cellular carcinoma. Ayurveda has been using to treat several liver ailments, but its efficiency is poorly documented by means of scientific studies. High number of Aurveda liver tonics has been prescribing for chronic liver diseases and G.I. disorders. Thirteen classical Ayurveda formulations and eight medicinal plants mostly used by Ayurveda were reviewed along with scientific studies. Arogyavardhini vati is highest prescribing medicine in liver disorders. Haridra, Katuki, chireeta, punnanava, kiratatikta, Bhumi amalaki are commonest single herb used by the herbalist and Ayurveda physician in the treatment of Jaundice and other liver disorders. Many grey areas of hepato billiary disorders can be addressed through scientific research in Ayurveda.

show abstract

“…[18] Safety of Arogyavardhini Vati on liver, kidney, and brain has been evaluated in earlier studies. [19] Hence, considering the antioxidant, anti-inflammatory, and hypolipidemic property, this study was designed to study the effect of Arogyavardhini Vati and Arjuna powder in dyslipidemic patients.…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy evaluation of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) in dyslipidemia patients: A pilot prospective cohort clinical study

Kumar

Srivastava

Sharma

et al. 2012

AYU

Self Cite

View full text Add to dashboard Cite

Cardiovascular disease has multifaceted in which dyslipidemia, inflammation, and immunity play an important role. Arjuna powder and Arogyavardhini Vati used for centuries has potential for combating these factors. Therefore, the objective of this study was to evaluate the safety and efficacy of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) for dyslipidemia patients. Total of 108 patients were screened at CGHS Ayurvedic Hospital, New Delhi. Ninety-six patients satisfied inclusion criteria, and signed informed consent and detailed medical history was recorded. Arjuna powder (5 g, BD) for 3 weeks and then Arogyavardhini Vati (500 mg, BD) for 4 weeks were prescribed to the patients. The primary efficacy endpoint was reduction in serum total cholesterol, LDL, triglycerides, and increased HDL levels. Secondary endpoints included reduction in serum C-Reactive Protein (CRP) and blood glucose levels. Safety assessments included hepatic function (aminotransferase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), bilirubin, and β2 microglobulin), renal function (urea and creatinine and NGAL) tests, and urine mercury level. The study was completed by 87 patients. The male and female patients were 65.5% (57/87) and 34.5% (30/87), respectively. There was a significant reduction in total cholesterol, LDL, triglycerides, CRP, and blood glucose. However, raised HDL level was also observed. Safety assessment results showed no significant change in serum ALT, AST, ALP and bilirubin, urea, creatinine β2 microglobulin, and NGAL levels at the end of study as compared to the baseline levels. In conclusion, the results of the present prospective cohort study showed that Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) is safe and effective for dyslipidemia.

show abstract

Safety evaluation of an Ayurvedic medicine, Arogyavardhini vati on brain, liver and kidney in rats

Cited by 39 publications

References 34 publications

The hypolipidemic activity of Ayurvedic medicine, Arogyavardhini vati in Triton WR-1339-induced hyperlipidemic rats: A comparison with fenofibrate

The hypolipidemic activity of Ayurvedic medicine, Arogyavardhini vati in Triton WR-1339-induced hyperlipidemic rats: A comparison with fenofibrate

Ayurvedic Intervention for Hepatobiliary Disorders: Current Scenario and Future Prospect

Safety and efficacy evaluation of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) in dyslipidemia patients: A pilot prospective cohort clinical study

Contact Info

Product

Resources

About